384 related articles for article (PubMed ID: 18628480)
1. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Wu L; Parton A; Lu L; Adams M; Schafer P; Bartlett JB
Cancer Immunol Immunother; 2011 Jan; 60(1):61-73. PubMed ID: 20848094
[TBL] [Abstract][Full Text] [Related]
3. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.
Taylor RJ; Saloura V; Jain A; Goloubeva O; Wong S; Kronsberg S; Nagilla M; Silpino L; de Souza J; Seiwert T; Vokes E; Villaflor V; Cohen EE
Cancer Immunol Res; 2015 May; 3(5):567-74. PubMed ID: 25769300
[TBL] [Abstract][Full Text] [Related]
5. Differential regulation of human monocytes and NK cells by antibody-opsonized tumors.
Yin J; Albers AJ; Smith TS; Riddell GT; Richards JO
Cancer Immunol Immunother; 2018 Aug; 67(8):1239-1250. PubMed ID: 29855696
[TBL] [Abstract][Full Text] [Related]
6. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
[TBL] [Abstract][Full Text] [Related]
7. A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.
Collier-Bain HD; Emery A; Causer AJ; Brown FF; Oliver R; Dutton D; Crowe J; Augustine D; Graby J; Leach S; Eddy R; Rothschild-Rodriguez D; Gray JC; Cragg MS; Cleary KL; Moore S; Murray J; Turner JE; Campbell JP
Brain Behav Immun; 2024 May; 118():468-479. PubMed ID: 38503395
[TBL] [Abstract][Full Text] [Related]
8. T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC.
Arora J; Ayyappan S; Yin C; Smith BJ; Lemke-Miltner CD; Wang Z; Farooq U; Weiner GJ
Blood; 2024 May; 143(18):1816-1824. PubMed ID: 38457360
[TBL] [Abstract][Full Text] [Related]
9. NK cell-mediated antibody-dependent cellular cytotoxicity is enhanced by tamoxifen in HER2/neu non-amplified, but not HER2/neu-amplified, breast cancer cells.
Richards JO; Albers AJ; Smith TS; Tjoe JA
Cancer Immunol Immunother; 2016 Nov; 65(11):1325-1335. PubMed ID: 27573917
[TBL] [Abstract][Full Text] [Related]
10. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
Hatjiharissi E; Xu L; Santos DD; Hunter ZR; Ciccarelli BT; Verselis S; Modica M; Cao Y; Manning RJ; Leleu X; Dimmock EA; Kortsaris A; Mitsiades C; Anderson KC; Fox EA; Treon SP
Blood; 2007 Oct; 110(7):2561-4. PubMed ID: 17475906
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Zhu D; Corral LG; Fleming YW; Stein B
Cancer Immunol Immunother; 2008 Dec; 57(12):1849-59. PubMed ID: 18392823
[TBL] [Abstract][Full Text] [Related]
12. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
13. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity.
Boissel L; Betancur-Boissel M; Lu W; Krause DS; Van Etten RA; Wels WS; Klingemann H
Oncoimmunology; 2013 Oct; 2(10):e26527. PubMed ID: 24404423
[TBL] [Abstract][Full Text] [Related]
14. A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Desroys du Roure P; Lajoie L; Mallavialle A; Alcaraz LB; Mansouri H; Fenou L; Garambois V; Rubio L; David T; Coenon L; Boissière-Michot F; Chateau MC; Ngo G; Jarlier M; Villalba M; Martineau P; Laurent-Matha V; Roger P; Guiu S; Chardès T; Gros L; Liaudet-Coopman E
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290768
[TBL] [Abstract][Full Text] [Related]
15. Engineering of CD34+ progenitor-derived natural killer cells with higher-affinity CD16a for enhanced antibody-dependent cellular cytotoxicity.
van Hauten PMM; Hooijmaijers L; Vidal-Manrique M; van der Waart AB; Hobo W; Wu J; Blijlevens NMA; Jansen JH; Walcheck B; Schaap NPM; de Jonge PKJD; Dolstra H
Cytotherapy; 2024 Mar; 26(3):252-260. PubMed ID: 38127030
[TBL] [Abstract][Full Text] [Related]
16. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
Panaampon J; Kariya R; Okada S
Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
[TBL] [Abstract][Full Text] [Related]
18. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
Müller T; Uherek C; Maki G; Chow KU; Schimpf A; Klingemann HG; Tonn T; Wels WS
Cancer Immunol Immunother; 2008 Mar; 57(3):411-23. PubMed ID: 17717662
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
20. The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells.
Abdullah N; Greenman J; Pimenidou A; Topping KP; Monson JR
Cancer Immunol Immunother; 1999 Dec; 48(9):517-24. PubMed ID: 10602889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
